|
1
|
Grönberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003.PubMed/NCBI
|
|
2
|
Ondrušová M and Ondruš D: The occurence
and mortality from prostate cancer in Slovakia and abroad.
Onkológia (Bratisl.). 4:272–274. 2009.(In Slovak).
|
|
3
|
Plesko I, Obsitníkova A, Cuninkova M,
Tomasek L, Stefanakova D and Kubik A: Increasing occurrence of
urological cancers in Slovakia. Neoplasma. 51:248–254.
2004.PubMed/NCBI
|
|
4
|
Khan N, Afaq F and Mukhtar H: Lifestyle as
risk factor for cancer: evidence from human studies. Cancer Lett.
293:133–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stein QP and Flanagan JD: Genetic and
familial factors influencing breast, colon, prostate and lung
cancers. S D Med. 16–22. 2010.PubMed/NCBI
|
|
6
|
Sánchez-Visconti G, Herrero L, Rabadán M,
Pereira I and Ruiz-Torres A: Ageing and prostate: age-related
changes in androgen receptors of epithelial cells from benign
hypertrophic glands compared with cancer. Mech Ageing Dev.
82:19–29. 1995.PubMed/NCBI
|
|
7
|
Brawley OW, Jani AB and Master V: Prostate
cancer and race. Curr Probl Cancer. 31:211–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sivonova MK, Dobrota D, Matakova T,
Dusenka R, Grobarcikova S, et al: Microsomal epoxide hydrolase
polymorphisms, cigarette smoking and prostate cancer risk in the
Slovak population. Neoplasma. 59:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Imamoto T, Suzuki H, Utsumi T, Endo T,
Takano M, et al: Association between serum sex hormone levels and
prostate cancer: effect of prostate cancer on serum testosterone
levels. Future Oncol. 5:1005–1013. 2009. View Article : Google Scholar
|
|
10
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van der Kwast TH, Schalken J, Ruizeveld de
Winter JA, van Vroonhoven CC, et al: Androgen receptors in
endocrine-therapy-resistant human prostate cancer. Int J Cancer.
48:189–193. 1991.PubMed/NCBI
|
|
12
|
Li X, Huang Y, Fu X, Chen C, Zhang D, et
al: Meta-analysis of three polymorphisms in the
steroid-5-α-reductase, α polypeptide 2 gene (SRD5A2) and risk of
prostate cancer. Mutagenesis. 26:371–383. 2011.PubMed/NCBI
|
|
13
|
Wilbert DM, Griffin JE and Wilson JD:
Characterization of the cytosol androgen receptor of the human
prostate. J Clin Endocrinol Metab. 56:113–120. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coffey DS: The Molecular Biology of the
Prostate. Prostate Diseases. Lepor H and Lawson RK: Saunders;
Philadelphia, PA: pp. 28–56. 1993
|
|
15
|
Ross RK, Bernstein L, Lobo RA, Shimizu FZ,
Stanczyk FZ, et al: 5-α-reductase activity and risk of prostate
cancer among Japanese and US white and black males. Lancet.
339:887–889. 1992.
|
|
16
|
Wu AH, Whittemore AS, Kolonel LN, John EM,
Gallagher RP, et al: Serum androgens and sex-hormone binding
globulins in relation to lifestyle factors in older
African-American, white, and Asian men in the United States and
Canada. Cancer Epidemiol Biomarkers Prev. 4:735–741. 1995.
|
|
17
|
Ntais C, Polycarpou A and Ioannidis JP:
SRD5A2 gene polymorphisms and the risk of prostate cancer: a
meta-analysis. Cancer Epidemiol Biomarkers Prev. 12:618–624.
2003.PubMed/NCBI
|
|
18
|
Montgomery RB, Mostaghel EA, Vessella R,
Hess DL, Kalhorn TF, et al: Maintenance of intratumoral androgens
in metastatic prostate cancer: a mechanism for castration-resistant
tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reichardt JK, Makridakis N, Henderson BE,
Yu MC, Pike MC and Ross RK: Genetic variability of the human SRD5A2
gene: implications for prostate cancer risk. Cancer Res.
55:3973–3975. 1995.PubMed/NCBI
|
|
20
|
Scariano JK, Treat E, Alba F, Nelson H,
Ness SA and Smith AY: The SRD5A2 V89L polymorphism is associated
with severity of disease in men with early onset prostate cancer.
Prostate. 68:1798–1805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boger-Megiddo I, Weiss NS, Barnett MJ,
Goodman GE and Chen CH: V89L polymorphisms of the 5α-reductase Type
II gene (SRD5A2), endogenous sex hormones, and prostate cancer
risk. Cancer Epidemiol Biomarkers Prev. 17:286–291. 2008.
|
|
22
|
Hsing AW, Chen C, Chokkalingam AP, Gao YT,
Dightman DA, et al: Polymorphic markers in the SRD5A2 gene and
prostate cancer risk: a population-based case-control study. Cancer
Epidemol Biomarkers Prev. 10:1077–1082. 2001.PubMed/NCBI
|
|
23
|
Makridakis NM, di Salle E and Reichardt
JK: Biochemical and pharmacogenetic dissection of human steroid
5a-reductase type II. Pharmacogenetics. 10:407–413. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allen NE, Forrest MS and Key TJ: The
association between polymorphisms in the CYP17 and 5α-reductase
(SRD5A2) genes and serum androgen concentrations in men. Cancer
Epidemiol Biomarkers Prev. 10:185–189. 2001.
|
|
25
|
Febbo PG, Kantoff PW, Platz EA, et al: The
V89L polymorphism in the 5α-reductase type 2 gene and risk of
prostate cancer. Cancer Res. 59:5878–5881. 1999.
|
|
26
|
Giwercman YL, Abrahamsoon PA, Giwercman A,
Gadaleanu V and Ahlgren G: The 5α-reductase type II A49T and V89L
high-activity allelic variants are more common in men with prostate
cancer compared with the general population. Eur Urol. 48:679–685.
2005.
|
|
27
|
Berndt SI, Chatterjee N, Huang WY, et al:
Variant in sex hormone-binding globulin gene and the risk of
prostate cancer. Cancer Epidemiol Biomarkers Prev. 16:165–168.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Coates RJ, Gwinn M, Khoury MJ, et
al: Steroid 5-α-reductase Type 2 (SRD5A2) gene polymorphisms and
risk of prostate cancer: a HuGE review. Am J Epidemiol. 171:1–13.
2010.
|
|
29
|
Schatzl G, Madersbacher S, Gsur A, et al:
Association of polymorphisms within androgen receptor,
5α-reductase, and PSA genes with prostate volume, clinical
parameters, and endocrine status in elderly men. Prostate.
52:130–138. 2002.
|
|
30
|
Wang CH, Tao W, Chen Q, Hu H, Wen XY, et
al: SRD5A2 V89L polymorphism and prostate cancer risk:
Meta-analysis. The Prostate. 70:170–178. 2010.PubMed/NCBI
|
|
31
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL; ISUP Grading Committee. The 2005 International Society
of Urological Pathology (ISUP) Consensus Conference on Gleason
grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deantoni EP: Age-specific reference ranges
for PSA in the detection of prostate cancer. Oncology (Williston
Park). 11:475–482. 485–486. 1997.PubMed/NCBI
|
|
33
|
Ausubel F, Brent R, Kingston R, Moore D,
Seidman JG, Smith J and Struhl K: Short Protocols in Molecular
Biology. 3rd edition. (Unit 21)John Wiley & Sons; New York, NY:
pp. 2–3. 1995
|
|
34
|
Cicek MS, Conti DV, Curran A, Neville PJ,
Paris PL, et al: Association of prostate cancer risk and
aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the
AR. The Prostate. 59:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lunn RM, Bell DA, Mohler JL and Taylor JA:
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and
steroid reductase (SRD5A2). Carcinogenesis. 20:1727–1731. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ross RK, Bernstein L, Lobo RA, Shimizu H,
Stanczyk FZ, et al: 5a-reductase activity and risk of prostate
cancer among Japanese and U.S. white and black males. Lancet.
339:887–889. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Makridakis N, Ross RK, Pike MC, Chang L,
Stanczyk FZ, et al: A prevalent missense substitution that
modulates activity of prostatic steroid 5a-reductase. Cancer Res.
57:1020–1022. 1997.PubMed/NCBI
|
|
38
|
Zeigler-Johnson CM, Walker AH, Mancke B,
et al: Ethnic differences in the frequency of prostate cancer
susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 54:13–21.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang J, Tang NL, Ohlsson C, Eriksson AL,
Vandenput L, et al: Association of SRD5A2 variants and serum
androstane-3α, 17beta-diol glucuronide concentration in Chinese
elderly men. Clin Chem. 56:1742–1749. 2010.PubMed/NCBI
|
|
40
|
Hayes VM, Severi G, Padilla EJD and Morris
HA: 5α-reductase type 2 gene variant associations with prostate
cancer risk, circulating hormone levels and androgenetic alopecia.
Int J Cancer. 120:776–780. 2006.
|
|
41
|
Allen NE, Forrest MS and Key TJ: The
association between polymorphisms in the CYP17 and 5alpha-reductase
(SRD5A2) genes and serum androgen concentrations in men. Cancer
Epidemiol Biomarkers Prev. 10:185–189. 2001.
|
|
42
|
Forrest MS, Edwards SM, Houlston R,
Kote-Jarai Z, Key T, et al: Association between hormonal genetic
polymorphisms and early-onset prostate cancer. Prostate Cancer and
Prostatic Diseases. 8:95–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Allen NE, Reichardt JK, Nguyen H and Key
TJ: Association between two polymorphisms in the SRD5A2 gene and
serum androgen concentrations in British men. Cancer Epidemiol
Biomarkers Prev. 12:578–81. 2003.PubMed/NCBI
|
